Phase II Study of Bevacizumab, Cisplatin, and Docetaxel Plus Maintenance Bevacizumab as First-Line Treatment for Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer Combined With Exploratory Analysis of Circulating Endothelial Cells: Thoracic Oncology Research Group (TORG)1016
BMC Cancer - United Kingdom
doi 10.1186/s12885-018-4150-y
Full Text
Open PDFAbstract
Available in full text
Date
March 2, 2018
Authors
Publisher
Springer Science and Business Media LLC